Výsledky vyhledávání - "E W, Gascoigne"

A retrospective survey on the safety of Replenate®, a high-purity factor VIII concentrate

Autor: E W, Gascoigne, C H, Dash, C, Harman, D, Wilmot

Publikováno v: Pharmacoepidemiology and Drug Safety. 13:243-252

To assess the safety of a highly purified, plasma-derived factor VIII concentrate (Replenate) in routine clinical use.Following guidelines entitled safety assessment of marketed medicines (SAMM), safety data were collected in the UK on 194 patients w

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::35d870d0d2887514255b4b82a9eb0e8f
https://doi.org/10.1002/pds.956

Zobrazit plný text záznamu

A retrospective survey on the safety of Replenine®, a high-purity factor IX concentrate

Autor: D. Wilmot, C. Harman, C. H. Dash, E. W. Gascoigne

Publikováno v: Pharmacoepidemiology and Drug Safety. 13:187-195

Purpose To assess the safety of a highly purified, plasma-derived factor VIII concentrate (Replenate®) in routine clinical use. Methods Following guidelines entitled safety assessment of marketed medicines (SAMM), safety data were collected in the U

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::99874df5ce1e4fa2adfa8270daee655b
https://doi.org/10.1002/pds.911

Zobrazit plný text záznamu

Solvent/detergent treatment does not alter the tolerance or uptake of human normal immunoglobulin for intramuscular injection

Autor: G. P. Mould, J. A. Sutton, E. W. Gascoigne, C.H. Dash, P. Matejtschuk

Publikováno v: Vox Sanguinis. 80:151-158

Background and Objectives The tolerability and pharmacokinetics of a solvent/detergent-treated intramuscular immunoglobulin were compared with those of the standard product. Materials and Methods Single, 750-mg intramuscular (i.m.) injections were ad

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a16b461fe1c3d071b5a23bad387b1e34
https://doi.org/10.1046/j.1423-0410.2001.00026.x

Zobrazit plný text záznamu

A retrospective survey on the safety of Replenine, a high-purity factor IX concentrate

Autor: E W, Gascoigne, C H, Dash, C, Harman, D, Wilmot

Publikováno v: Pharmacoepidemiology and drug safety. 13(3)

To assess the safety of a plasma-derived highly purified factor IX concentrate (Replenine) in routine clinical use.Following guidelines entitled Safety Assessment of Marketed Medicines (SAMM), safety data were collected in the UK by retrospective rev

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::a51280e7240101865c3ebd5a594346e1
https://pubmed.ncbi.nlm.nih.gov/15072119

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání